European Biotechnology Network
  • Home
  • About
    • Team
    • Advanced Members
  • Join
  • Biotech Label
  • Job Market
  • Climate Project
  • Calendar
  • Contact
  • Menu Menu

Archive for category: News

You are here: Home1 / News / Events2

GSK strengthens food allergy ambitions with $2.2bn RAPT Therapeutics acquisition

20th January 2026/in News/by Thomas Gabrielczyk
https://european-biotechnology.net/wp-content/uploads/2026/01/markus-winkler-ktkswIQJY1E-unsplash-1030x687-1.jpg 687 1030 Thomas Gabrielczyk /wp-content/uploads/2019/12/ebn-1-300x135.png Thomas Gabrielczyk2026-01-20 12:40:102026-01-20 12:40:10GSK strengthens food allergy ambitions with $2.2bn RAPT Therapeutics acquisition

Heidelberg-based Exciva secures €51M to tackle agitation in Alzheimer’s care

20th January 2026/in News/by Thomas Gabrielczyk
https://european-biotechnology.net/wp-content/uploads/2026/01/V2-960x540_realistic-scene-with-elderly-care-senior-people.jpeg.webp 540 960 Thomas Gabrielczyk /wp-content/uploads/2019/12/ebn-1-300x135.png Thomas Gabrielczyk2026-01-20 09:27:182026-01-20 09:27:18Heidelberg-based Exciva secures €51M to tackle agitation in Alzheimer’s care

AgomAb files for U.S. IPO as fibrosis-focused pipeline moves deeper into the clinic

19th January 2026/in News/by Thomas Gabrielczyk
https://european-biotechnology.net/wp-content/uploads/2026/01/pexels-markus-winkler-1430818-30901559.jpg 427 640 Thomas Gabrielczyk /wp-content/uploads/2019/12/ebn-1-300x135.png Thomas Gabrielczyk2026-01-19 16:36:482026-01-19 16:36:48AgomAb files for U.S. IPO as fibrosis-focused pipeline moves deeper into the clinic

Genmab and AbbVie’s epcoritamab fails in phase 3 lymphoma study

19th January 2026/in News/by Thomas Gabrielczyk
https://european-biotechnology.net/wp-content/uploads/2026/01/markus-spiske-KTuHfak_EEk-unsplash.jpg 427 640 Thomas Gabrielczyk /wp-content/uploads/2019/12/ebn-1-300x135.png Thomas Gabrielczyk2026-01-19 09:03:422026-01-19 09:03:42Genmab and AbbVie’s epcoritamab fails in phase 3 lymphoma study

Genethon licenses core AB-1009 technology to AskBio after IND clearance

16th January 2026/in News/by Thomas Gabrielczyk
https://european-biotechnology.net/wp-content/uploads/2026/01/pexels-karola-g-5398881-1030x687-1.jpg 687 1030 Thomas Gabrielczyk /wp-content/uploads/2019/12/ebn-1-300x135.png Thomas Gabrielczyk2026-01-16 16:35:232026-01-16 16:35:23Genethon licenses core AB-1009 technology to AskBio after IND clearance

EMA and FDA join forces: Aligned principles on AI use in drug development

16th January 2026/in News/by Thomas Gabrielczyk
https://european-biotechnology.net/wp-content/uploads/2026/01/pexels-tara-winstead-8386440-1030x687-1.jpg 687 1030 Thomas Gabrielczyk /wp-content/uploads/2019/12/ebn-1-300x135.png Thomas Gabrielczyk2026-01-16 08:12:232026-01-16 08:12:23EMA and FDA join forces: Aligned principles on AI use in drug development

With a €6.26M round, QLi5 doubles down on proteasome-based ADC payloads

15th January 2026/in News/by Thomas Gabrielczyk
https://european-biotechnology.net/wp-content/uploads/2026/01/mathieu-stern-1zO4O3Z0UJA-unsplash.jpg 427 640 Thomas Gabrielczyk /wp-content/uploads/2019/12/ebn-1-300x135.png Thomas Gabrielczyk2026-01-15 16:54:552026-01-15 16:54:55With a €6.26M round, QLi5 doubles down on proteasome-based ADC payloads

Novo Nordisk Foundation commits DKK 5.5 billion to scale European biotech innovation

15th January 2026/in News/by Thomas Gabrielczyk
https://european-biotechnology.net/wp-content/uploads/2026/01/EZ_24-09-05_Demoday_17666-1030x773-1.jpg 773 1030 Thomas Gabrielczyk /wp-content/uploads/2019/12/ebn-1-300x135.png Thomas Gabrielczyk2026-01-15 12:58:152026-01-15 12:58:15Novo Nordisk Foundation commits DKK 5.5 billion to scale European biotech innovation

Munich’s Innovative Molecules signs €125M partnership with Alfasigma to advance HSV encephalitis antiviral

15th January 2026/in News/by Thomas Gabrielczyk
https://european-biotechnology.net/wp-content/uploads/2026/01/cdc_23311_lores.jpg 539 960 Thomas Gabrielczyk /wp-content/uploads/2019/12/ebn-1-300x135.png Thomas Gabrielczyk2026-01-15 09:25:422026-01-15 11:32:03Munich’s Innovative Molecules signs €125M partnership with Alfasigma to advance HSV encephalitis antiviral

Faster to the bedside: Collaboration in cell therapy of Fresenius Kabi and TQ Therapeutics

14th January 2026/in News/by Thomas Gabrielczyk
https://european-biotechnology.net/wp-content/uploads/2026/01/tq-therapeutics-team-v2-device-web.jpeg 540 960 Thomas Gabrielczyk /wp-content/uploads/2019/12/ebn-1-300x135.png Thomas Gabrielczyk2026-01-14 14:13:002026-01-14 17:02:03Faster to the bedside: Collaboration in cell therapy of Fresenius Kabi and TQ Therapeutics
Page 4 of 150«‹23456›»
  • © EBNet by ZENTRALWERK GmbH 2008 - 2025
  • Imprint
  • Privacy Statement
Scroll to top Scroll to top Scroll to top